Epitomee Medical Ltd · TASE:EPIT
Epitomee Medical — Investor Presentation (May 2026)
31 slides from Epitomee Medical's investor presentation, May 2026
Slide 1: Global Scaling & Market Entry Strategy - Weight Management
Global Scaling & Market Entry Strategy- Weight Management Commercial rollout, Market Entry, Manufacturing Scale-Up and Growth May 2026 Investor Briefing 1
Slide 2: Company Overview
Company Overview Epitomee® Weight Management Capsule Commercial roll out, status, next steps Manufacturing scale up Summary 2
Slide 3: Management Team
Management Team Shimon Eckhouse, PhD Dan Hashimshony, PhD Co-founder and Chairman Chief Executive Officer Founder of Syneron Nasdaq:ELOS & Lumenis Founder & CEO-Dune Medical Devices Nasdaq:LMNS, Sofwave Medical TLV: SOFW and others Chief Scientist X-technologies, and others Gal Yael Gil Maya Alon Ha
Slide 4: Disclaimer
Disclaimer This presentation (the “Presentation”) is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Epitomee Medical Ltd. (the “Company”) and should not be regarded as a recommendation or an opinion on such
Slide 5: Key Milestones Timeline
Key Milestones Timeline From FDA clearance, September 2024 to commercial rollout May 2026 US Online Pharmacy International Rafa Distribution Germany Orders FDA Clearance Revive agreement Shipments Commercial agreement 12-month orders Pivotal regulatory with Rafa in Israel Online pharmacy for Rx tota
Slide 6: Epitomee's Strategic Focus Areas: Current Market and Pipeline
Epitomee’s Strategic Focus Areas: Current Market and Pipeline Current Pipeline Weight Management Biologics Drug Market2: market1: size and trends size and trends ~$180B ~$0.5T ~$400B+ by 2035 ~$1T+ by 2035 1. Based on Towards Health Care market report 2026- 2. Based on Precedence Research 2026 – htt
Slide 7: GLP1 Market Size Outlook
GLP1 Market Size Outlook Global GLP1 market • This growth is driven by $180 $160 $157B rising obesity rates, and $140 advancements in weight $120 management products. $100 $Billion $80 $62B $60 $40 $20 $- 2025 2035 ResearchAndMarkets.com, Jan 2026 Note: Market size estimates vary significantly depen
Slide 8: The GLP1 success created the weight maintenance gap
The GLP1 success created the “weight maintenance” GAP; Epitomee capsule is Closing the Gap 65% 65% of GLP1 users stop using the medication. Post GLP1 users require Discontinue weight maintenance. within 1st 12 months JAMA Network Open, 2025 8
Slide 9: The GLP-1 Reality: High Regain & High Discontinuation
The -GLP-1 Reality: High Regain & High Discontinuation 65% Discontinue GLP-1s 2/3 2/3 Weight regain Quick Weight after regain stopping 1:2 Side Effects within 12 months after stopping Short & long term Black Box warning Adverse Effects of GLP-1 Receptor JAMA Network Open, Wegovy.com Wegovy.com Wegov
Slide 10: Target Patient Segments
Target Patient Segments Patients seeking long-term, side-effect-free alternatives post GLP-1 therapy ✓ Post GLP-1 GLP-1 Adverse Health Conscious BMI 25–27 Successful users seeking a Intolerance, contraindications, Concerns over side effects, long-term exit strategy or comorbidities that rule out lon
Slide 11: Epitomee: An Alternative for a Wider Audience
Epitomee : An Alternative for a Wider Audience ® Epitomee® capsule is an Rx medical device offering weight management solution for individuals with a BMI 25 to 40 (with/without co-morbidities), alongside diet and exercise. Indicated for adults: Distinctive of Indication: BMI 25 to 40 • With or witho
Slide 12: The Epitomee Capsule
The Epitomee® Capsule 12
Slide 13: The Product and Packaging - 4 Weeks treatment box
The Product and Packaging – 4 Weeks treatment box 13
Slide 14: Epitomee Capsule
Epitomee® Capsule A non-drug, clinically supported capsule that by expanding in the stomach, helping users feel full, eat less, and stay on track FDA-cleared, CE and AMAR-approved , Rx medical device Drug-free, hormone-free and no injection Integrates seamlessly into diet & exercise routines1,2 Dosi
Slide 15: Introducing a Novel Weight Management Modality
Introducing a Novel Weight Management Modality Today’s standard of care A proven, safe, drug-free alternative The Epitomee® Capsule Gastric Balloons GLP-1 GLP-1 Promotes fullness & satiety, no side or Lap-Bands Injections Pills effects*, drug-free, clinically Clinical insertion procedure Hormonelike
Slide 16: The Growing Landscape of Supporting Epitomee's Efficacy and Health Benefits
The Growing Landscape of Supporting Epitomee’s Efficacy and Health Benefits Accumulation of Multiple Peer-Reviewed Clinical Publications
Slide 17: Additional Epitomee Health Benefits in Peer-Reviewed Literature
Additional Epitomee® Health Benefits in Peer-Reviewed Literature Early Waistline Weight Improved Improvement Improvements in Safe & response3 reduction5,2 management1-6 Quality of life4 Metabolic cardiometabolic drug free1-6 syndrome2 risk factors2 1. Ard JD, Ryan DH, O’Neil PM, et al. Efficacy and
Slide 18: IP - Multiple Patent Families, Covering the Product & Pipeline
IP- Multiple Patent Families, Covering the Product & Pipeline 46 GRANTED 80 PATENTS 34 PENDING IN PROCESS 18
Slide 19: Commercial Rollout & manufacturing scale up
Commercial Rollout & manufacturing scale up 19
Slide 20: Epitomee's dual-track growth strategy
Epitomee’s dual-track growth strategy: In the U.S., a 'click-to-doorstep' operation; and OUS expansion through local distributors Czeck R & Activ territories Slovakia Germany Pending registration Spain USA Europe – Cleared for the EU market, CE mark Mexico Israel – Cleared by the ministry of India h
Slide 21: Israel: The Home-base Market
Israel market Israel: The Home-base Market The Opportunity: Almost 60% of Israelis are Overweight* 63% 57% 80% of Israeli men are overweight of Israeli women are overweight of diets for weight loss fail — weight regained within a year Go-to-Market: ISRAEL — The Home-Base Market Exclusive Distributor
Slide 22: Capturing Europe's Weight Management Opportunity
Capturing Europe’s Weight Management Opportunity $8B+ $22B 12% CAGR European GLP1 market revenue (2025) Projected GLP1 market size by 2033 Rapid growth through 2033 Our Go-to-Market Strategy Market Approach Distribution Partners Operations Localized strategies tailored to Partnering with early-adopt
Slide 23: US Market Opportunity
US Market Opportunity 1 172M Americans qualify for medical weight management1 172M Eligible US patients on label Patients: seeking long-term, side-effect-free Opportunity 2 alternatives post, pre, or instead of GLP-1 therapy Fill the massive gap between lifestyle, diet failure, and drug therapy opti
Slide 24: US 1st Partnership: Revive Health
US 1st Partnership: Revive Health What is Revive? An integrated healthcare platform, providing health services for employers. serving 1,600+ Employers (US companies) and 4M members – (employees). Via virtual care designed for self-insured employers Revive partnership Launch Q3-Q4* Integrating Epitom
Slide 25: The next stage: Click to Doorstep operation
The next stage: “Click to Doorstep” operation A streamlined operation driven by targeted digital marketing and telehealth partnerships 1 2 3 4 Discover Consult Fulfillment Deliver Targeted DTC ads via Meta, Telehealth intake form and virtual Physician approves prescription; Epitomee Capsule shipped
Slide 26: Supplied orders and short-term binding orders for the next 12 months
Supplied orders and short-term binding orders for the next 12 months Supplied orders and short-term binding orders (thousands $) • Included supplied orders and Future binding orders • Not including USA • Not including any of the $600 projections that are not binding $2,800 Total $6.9M $3,500 Supplie
Slide 27: Estimated Manufacturing Capacity: Scale-Up Plan
Estimated Manufacturing capacity : Scale-Up plan Estimated Manufacturing capacity (in thousands boxes) 1000 ~48M Capsules 900 800 Thousands boxes 700 600 50k Boxes ~2.7M ~24M Capsules ~24M Capsules Capsules. 500 At the end of 2026, we 400 estimate a yearly ~15M Capsules 864 Manufacturing 300 capacit
Slide 28: State-of-the-Art Production Process
State-of-the-Art Production Process Raw material Thin film coating Robotic assembly Proprietary information of Epitomee Medical . Not to be reproduced or disclosed to others without prior written approval
Slide 29: Key Risks & Barriers at a Glance
Key Risks & Barriers at a Glance Regulatory Market & Competitive Operational & Financial Post-Market Compliance GLP-1 Oral Advances Manufacturing Scale-Up International Approvals Pricing Uncertainty Single-Facility Risk Validation process of new Physician Adoption Capacity vs. Demand Gap machines DT
Slide 30: 2026 Milestones & Timeline
2026 Milestones & Timeline Global Maximize Expansion US Market Partnerships ROW&EU Penetration Optimize revenue from all Secure new partnerships Launch Revive online existing signed distribution and expand into untapped pharmacies and employer agreements international territories healthcare* FOUNDAT
Slide 31: Thank you
Thank you Corporate Deck, January 2026 31